Article

XCath, a medical device company specializing in neuro-endovascular surgical robotics, secured $30 million in Series C funding, bringing total funding to $92 million. This funding will aid in the development of the world's first commercially-practical endovascular robot and support clinical telerobotic mechanical thrombectomy.

Crescent Enterprises co-led the investment round along with Dr. Fred Moll. In November 2025, XCath's Iris robotic system successfully performed surgeries on patients with complex brain aneurysms, reinforcing its leadership in endovascular robotics. The XCath robotic system is currently under development and not yet cleared for commercial distribution.